Skip Content
You are currently on the new version of our website. Access the old version .

Cancers, Volume 5, Issue 3

2013 September - 23 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (23)

  • Article
  • Open Access
17 Citations
7,777 Views
22 Pages

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy

  • Ludovic T. Nguyen,
  • Socheat Touch,
  • Hélène Nehme-Schuster,
  • Delphine Antoni,
  • Sokha Eav,
  • Jean-Baptiste Clavier,
  • Nicolas Bauer,
  • Céline Vigneron,
  • Roland Schott and
  • Georges Noël
  • + 1 author

24 September 2013

This study aimed to analyze the treatment and outcomes of older glioblastoma patients. Forty-four patients older than 70 years of age were referred to the Paul Strauss Center for chemotherapy and radiotherapy. The median age was 75.5 years old (range...

  • Concept Paper
  • Open Access
37 Citations
11,713 Views
14 Pages

10 September 2013

Among gynecological malignancies epithelial ovarian cancer (EOC) is the leading cause of death. Despite improvements in conventional chemotherapy combinations, the overall cure rate has remained mostly stable over the years, and only 10%–15% of patie...

  • Review
  • Open Access
63 Citations
11,089 Views
23 Pages

Leptin’s Pro-Angiogenic Signature in Breast Cancer

  • Ruben Rene Gonzalez-Perez,
  • Viola Lanier and
  • Gale Newman

6 September 2013

Obesity is linked to increased incidence of breast cancer. The precise causes and mechanisms of these morbid relationships are unknown. Contradictory data on leptin angiogenic actions have been published. However, accumulating evidence would suggest...

  • Review
  • Open Access
52 Citations
13,656 Views
20 Pages

Is Glioblastoma an Epigenetic Malignancy?

  • Marta Maleszewska and
  • Bozena Kaminska

3 September 2013

Epigenetic modifications control gene expression by regulating the access of nuclear proteins to their target DNA and have been implicated in both normal cell differentiation and oncogenic transformation. Epigenetic abnormalities can occur both as a...

  • Review
  • Open Access
8 Citations
9,084 Views
17 Pages

22 August 2013

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the t(9;22) translocation. As in most cancers, short telomeres are one of the features of CML cells, and telomere shortening accentuates as the disease progresses from t...

  • Review
  • Open Access
81 Citations
12,331 Views
17 Pages

Emerging Biomarkers in Glioblastoma

  • Mairéad G. McNamara,
  • Solmaz Sahebjam and
  • Warren P. Mason

22 August 2013

Glioblastoma, the most common primary brain tumor, has few available therapies providing significant improvement in survival. Molecular signatures associated with tumor aggressiveness as well as with disease progression and their relation to differen...

  • Review
  • Open Access
161 Citations
15,926 Views
29 Pages

Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

  • Matthias Van Woensel,
  • Nathalie Wauthoz,
  • Rémi Rosière,
  • Karim Amighi,
  • Véronique Mathieu,
  • Florence Lefranc,
  • Stefaan W. Van Gool and
  • Steven De Vleeschouwer

14 August 2013

Despite recent advances in tumor imaging and chemoradiotherapy, the median overall survival of patients diagnosed with glioblastoma multiforme does not exceed 15 months. Infiltration of glioma cells into the brain parenchyma, and the blood-brain bar...

  • Review
  • Open Access
79 Citations
19,375 Views
23 Pages

14 August 2013

Glioblastoma multiforme (GBM, WHO grade IV) is the most common and lethal subtype of primary brain tumor with a median overall survival of 15 months from the time of diagnosis. The presence in GBM of a cancer population displaying neural stem cell (N...

  • Review
  • Open Access
17 Citations
7,292 Views
14 Pages

14 August 2013

While vitamin D exhibits a multitude of cellular effects that can impact on cancer development and progression, this review focuses on its immune modulatory effects. These immune modulatory effects can be both direct and indirect. Compared to other c...

  • Review
  • Open Access
37 Citations
12,037 Views
22 Pages

9 August 2013

Epigenetic modifiers play important roles in fine-tuning the cellular transcriptome. Any imbalance in these processes may lead to abnormal transcriptional activity and thus result in disease state. Distortions of the epigenome have been reported in c...

  • Article
  • Open Access
25 Citations
8,313 Views
13 Pages

The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy

  • Laura K. Green,
  • Mathew A. Storey,
  • Elsie M. Williams,
  • Adam V. Patterson,
  • Jeff B. Smaill,
  • Janine N. Copp and
  • David F. Ackerley

8 August 2013

Bacterial nitroreductase enzymes that can efficiently catalyse the oxygen-independent reduction of prodrugs originally developed to target tumour hypoxia offer great potential for expanding the therapeutic range of these molecules to aerobic tumour r...

  • Review
  • Open Access
108 Citations
29,003 Views
16 Pages

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?

  • Amanda F. Swindall,
  • Jennifer A. Stanley and
  • Eddy S. Yang

26 July 2013

Oxidative stress induced by reactive oxygen species can result in DNA damage within cells and subsequently increase risk for carcinogenesis. This may be averted by repair of DNA damage through the base or nucleotide excision repair (BER/NER) pathways...

  • Article
  • Open Access
24 Citations
10,005 Views
26 Pages

Control of Oxidative Stress and Generation of Induced Pluripotent Stem Cell-like Cells by Jun Dimerization Protein 2

  • Shyh-Shin Chiou,
  • Sophie Sheng-Wen Wang,
  • Deng-Chyang Wu,
  • Ying-Chu Lin,
  • Li-Pin Kao,
  • Kung-Kai Kuo,
  • Chun-Chieh Wu,
  • Chee-Yin Chai,
  • Cheng-Lung Steve Lin and
  • Kazunari K. Yokoyama
  • + 13 authors

26 July 2013

We report here that the Jun dimerization protein 2 (JDP2) plays a critical role as a cofactor for the transcription factors nuclear factor-erythroid 2-related factor 2 (Nrf2) and MafK in the regulation of the antioxidants and production of reactive o...

  • Review
  • Open Access
37 Citations
10,441 Views
24 Pages

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

  • Antonino Grassadonia,
  • Pasquale Cioffi,
  • Felice Simiele,
  • Laura Iezzi,
  • Marinella Zilli and
  • Clara Natoli

25 July 2013

Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myel...

  • Article
  • Open Access
20 Citations
9,043 Views
18 Pages

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

  • Alessandro Natoni,
  • Mark R. E. Coyne,
  • Alan Jacobsen,
  • Michael D. Rainey,
  • Gemma O'Brien,
  • Sandra Healy,
  • Alessia Montagnoli,
  • Jürgen Moll,
  • Michael O'Dwyer and
  • Corrado Santocanale

24 July 2013

Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors...

  • Article
  • Open Access
54 Citations
7,361 Views
11 Pages

Head and Neck Sarcomas: A Comprehensive Cancer Center Experience

  • Mohamedtaki A. Tejani,
  • Thomas J. Galloway,
  • Miriam Lango,
  • John A. Ridge and
  • Margaret Von Mehren

15 July 2013

Head/neck sarcomas are rare, accounting for about 1% of head/neck malignancies and 5% of sarcomas. Outcomes have historically been worse in this group, due to anatomic constraints leading to difficulty in completely excising tumors, with high rates o...

  • Review
  • Open Access
37 Citations
11,922 Views
15 Pages

Utility of MRI Diffusion Techniques in the Evaluation of Tumors of the Head and Neck

  • José Pablo Martínez Barbero,
  • Inmaculada Rodríquez Jiménez,
  • Teodoro Martin Noguerol and
  • Antonio Luna Alcalá

5 July 2013

The use of diffusion-weighted imaging in the head and neck is an increasingly used technique that requires adaptation of the acquisition parameters. Parallel imaging and emerging techniques such as IVIM are playing a new role. The main indications fo...

  • Review
  • Open Access
16 Citations
11,730 Views
19 Pages

HEXIM1, a New Player in the p53 Pathway

  • Qiao Jing Lew,
  • Kai Ling Chu,
  • Yi Ling Chia,
  • Nge Cheong and
  • Sheng-Hao Chao

4 July 2013

Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb), which controls transcription elongation of RNA polymerase II and Tat transactivation of human immunodeficie...

  • Review
  • Open Access
15 Citations
9,924 Views
18 Pages

4 July 2013

Chromosomal instability (CIN) is a characteristic feature of cancer. In this review, we concentrate on mechanisms leading to CIN in myeloid neoplasia, i.e., myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The pathogenesis of myeloid n...

  • Review
  • Open Access
36 Citations
11,586 Views
23 Pages

Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications

  • Therese Liechtenstein,
  • Noemi Perez-Janices and
  • David Escors

2 July 2013

The success of immunotherapy against infectious diseases has shown us the powerful potential that such a treatment offers, and substantial work has been done to apply this strategy in the fight against cancer. Cancer is however a fiercer opponent tha...

  • Review
  • Open Access
37 Citations
12,373 Views
29 Pages

Alterations of 5-Hydroxymethylcytosine in Human Cancers

  • Christopher J. Mariani,
  • Jozef Madzo,
  • Erika L. Moen,
  • Ali Yesilkanal and
  • Lucy A. Godley

25 June 2013

Prior to 2009, 5-methylcytosine (5-mC) was thought to be the only biologically significant cytosine modification in mammalian DNA. With the discovery of the TET enzymes, which convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), howeve...

  • Review
  • Open Access
31 Citations
9,533 Views
23 Pages

Synthetic Genetic Targeting of Genome Instability in Cancer

  • Babu V. Sajesh,
  • Brent J. Guppy and
  • Kirk J. McManus

24 June 2013

Cancer is a leading cause of death throughout the World. A limitation of many current chemotherapeutic approaches is that their cytotoxic effects are not restricted to cancer cells, and adverse side effects can occur within normal tissues. Consequent...

  • Review
  • Open Access
23 Citations
10,088 Views
24 Pages

Influence of Levamisole and Other Angiogenesis Inhibitors on Angiogenesis and Endothelial Cell Morphology in Vitro

  • Tina Friis,
  • Anne-Marie Engel,
  • Christine D. Bendiksen,
  • Line S. Larsen and
  • Gunnar Houen

24 June 2013

Angiogenesis, the formation of new blood vessels from existing vessels is required for many physiological processes and for growth of solid tumors. Initiated by hypoxia, angiogenesis involves binding of angiogenic factors to endothelial cell (EC) rec...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694